Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CYP2C19 genotyping Clear all
Terminated No phase listed Observational

Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study

NCT00995514
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
4,471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Franklin Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated May 29, 2012 · Synced Sep 6, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56

NCT01235351
View directory record Official record
Conditions
Myocardial Infarction, Percutaneous Coronary Intervention
Interventions
Clopidogrel
Drug
Lead sponsor
The TIMI Study Group
Other
Eligibility
18 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 6, 2026, 2:56 AM EDT
Recruiting No phase listed Observational

Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke

NCT06292117
View directory record Official record
Conditions
Ischemic Stroke, CYP2C19 Polymorphism
Interventions
CYP2C19 Genotype
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 6, 2026, 2:56 AM EDT
Not listed Phase 4 Interventional

Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

NCT04502017
View directory record Official record
Conditions
Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion
Interventions
ASA plus Clopidogrel, Genetic-Tailored AntiThrombotic Strategy, Half-Dose of novel OAC
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 6, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype

NCT00651638
View directory record Official record
Conditions
Healthy
Interventions
Treatment with ARQ 197
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 18, 2008 · Synced Sep 6, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Tailored Antiplatelet Therapy Following PCI

NCT01742117
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome, Stenosis
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5,276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
26
States / cities
Scottsdale, Arizona • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 6, 2026, 2:56 AM EDT
Completed No phase listed Observational

Voriconazole Blood Levels and Toxicity

NCT00359541
View directory record Official record
Conditions
Pharmacology
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 6, 2026, 2:56 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

NCT06510699
View directory record Official record
Conditions
Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
Interventions
genotype-directed dosing with dosing software based on therapeutic drug monitoring
Other
Lead sponsor
The University of Queensland
Other
Eligibility
2 Years and older
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 6, 2026, 2:56 AM EDT
Terminated Not applicable Interventional

Thrombocyte Activity Reassessment and GEnoTyping for PCI(TARGET-PCI)

NCT01177592
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
VerifyNow, Verigene
Device
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 6, 2026, 2:56 AM EDT
Completed No phase listed Observational

Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy

NCT02724319
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
SpartanRX
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 6, 2026, 2:56 AM EDT
Active, not recruiting No phase listed Observational

Precision PCI Registry

NCT06143709
View directory record Official record
Conditions
Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
DNA sample collection
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1,643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 6, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Clopidogrel Monotherapy in Patients With High Bleeding Risk

NCT05223335
View directory record Official record
Conditions
Bleeding Complications
Interventions
Clopidogrel, Prasugrel, Tricagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 6, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Implementation of PPI Medication PGX Testing

NCT02794844
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Genotype Guided PPI Dosing
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 6, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole

NCT00668902
View directory record Official record
Conditions
Healthy
Interventions
[13C]Pantoprazole
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Sep 6, 2026, 2:56 AM EDT
Terminated Not applicable Interventional

IU Health Krannert Personalized Medicine Study

NCT02955121
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prescriber Access to Genetic Information
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 6, 2026, 2:56 AM EDT
Not listed Phase 4 Interventional

Implementing Precision Medicine Approaches to Guide Anti-platelet Selection

NCT04090281
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation MI, Unstable Angina (UA)
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 6, 2026, 2:56 AM EDT
Terminated Phase 4 Interventional Results available

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study

NCT01452152
View directory record Official record
Conditions
Cardiovascular Diseases, Acute Coronary Syndrome
Interventions
clopidogrel, prasugrel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years to 74 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Newark, Delaware • Baltimore, Maryland • Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 6, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

NCT03489863
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 6, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention

NCT02508116
View directory record Official record
Conditions
Acute Coronary Syndrome, Cardiovascular Diseases
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 6, 2026, 2:56 AM EDT
Completed No phase listed Observational

Genotype Information and Functional Testing Study

NCT00992420
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Sep 6, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Genotype on LY2216684

NCT01460381
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Quinidine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 6, 2026, 2:56 AM EDT
Withdrawn Early Phase 1 Interventional

CYP2C19 Genotype Predictor of Gastric Acid Suppression

NCT01824199
View directory record Official record
Conditions
Esophagitis
Interventions
Omeprazole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 6, 2026, 2:56 AM EDT
Recruiting Not applicable Interventional

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

NCT06943586
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack (TIA)
Interventions
CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
Genetic
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 6, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers

NCT00931073
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 17, 2009 · Synced Sep 6, 2026, 2:56 AM EDT